2022 World Conference on Lung Cancer (ePosters)-EP08.02-091. Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA

EP08.02-091. Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA

Pdf Summary

This study aimed to investigate the predictive value of dynamic changes in circulating tumor DNA (ctDNA) and ctDNA EGFR mutation status in patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors (TKIs). The analysis included 91 ctDNA samples from 28 patients at baseline, 4 weeks after TKI initiation, and at disease progression.<br /><br />The results showed that monitoring the clearance of EGFR in ctDNA is a promising and cost-effective method for assessing treatment response and predicting survival in EGFR-mutated NSCLC patients treated with EGFR-TKIs. The predictive value of ctDNA clearance was found to be similar to that of ctDNA surveillance.<br /><br />The patients were divided into three subgroups based on their ctDNA and EGFR status at Week 4: non-clearance group, only EGFR clearance group, and all-clearance group. The non-clearance group had a significantly worse progression-free survival (PFS) compared to the all-clearance group. The only EGFR clearance group had a similar PFS to the all-clearance group, which was longer than the non-clearance group. The all-clearance group also had a higher objective response rate (ORR) compared to the non-clearance group.<br /><br />These findings suggest that monitoring the clearance of EGFR in ctDNA can help identify patients who are more likely to benefit from EGFR-TKI treatment and have improved outcomes. This approach provides valuable information for personalized treatment decisions and disease management in EGFR-mutated NSCLC patients.<br /><br />In summary, this study demonstrates the predictive value of dynamic changes in ctDNA EGFR mutation status and ctDNA clearance in assessing response and predicting survival in EGFR-mutated NSCLC patients treated with EGFR-TKIs. These findings support the use of ctDNA monitoring as a valuable tool for disease monitoring and treatment guidance in this patient population.

Asset Subtitle

Yan Li

Meta Tag

Speaker Yan Li

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

ctDNA

EGFR mutation status

NSCLC

tyrosine kinase inhibitors

treatment response

predicting survival

ctDNA clearance

progression-free survival

objective response rate

personalized treatment decisions